Community Deployment of Bispecific Antibodies in Multiple Myeloma & Non-Hodgkin Lymphoma within RWJBarnabas Health/Rutgers Cancer Institute
| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Hematology/Oncology, Oncology, Pharmacy, Hospitalist, Emergency Medicine, Intensive Care |
| Credits Available: | 4.75 AMA PRA Category 1 Credits™ |
This curriculum is designed to address the operational, clinical, and logistical challenges of integrating bispecific antibody (bsAb) therapies across the RWJBarnabas Health system. Building on established academic protocols, the program guides community clinicians in adapting workflows for safe bsAb administration, clarifying team roles, and strengthening coordination with academic hubs. Through evidence-based modules and practical implementation strategies, participants from each RWJBarnabas Health site will enhance their ability to select and sequence bsAbs appropriately, manage toxicities, and ensure continuity of care and equitable access for patients with multiple myeloma and non-Hodgkin lymphoma.
CME/CE Accreditation Information
Itinerary
Part 1
Assessment of knowledge regarding bispecific antibody therapy in MM and NHL, including patient selection, treatment sequencing, safety monitoring, community implementation protocols, and long-term toxicity management strategies.
Overview of bispecific antibodies in MM and NHL, including mechanism of action, FDA-approved agents, emerging targets, clinical trial data, and evidence-based strategies for patient selection and treatment sequencing.
Protocol development for community-based bispecific antibody administration, including role delineation, toxicity management, REMS compliance, escalation pathways, and emergency response planning for CRS and ICANS
Infrastructure assessment, staff training, long-term toxicity monitoring, academic-community collaboration models, insurance navigation, and formulary alignment to ensure sustainable bispecific antibody programs in community settings.
Evaluation of learner knowledge following education on bispecific antibody therapy in MM and NHL, including patient selection, treatment sequencing, safety protocols, community implementation, and toxicity management strategies.
Define system-wide criteria for community vs. hub step-up dosing, streamline formularies and payer workflows, and identify scalable infrastructure, staffing, and operational standards to support safe, sustainable bsAb administration across all sites.
Part 2
RWJBarnabas plans mosunetuzumab for relapsed follicular lymphoma at a satellite site. Challenges include payer delays, incomplete formulary alignment, missing EMR toxicity flowsheets, vague after-hours escalation, and limited beds.
Michael, 67, receives teclistamab for R/R myeloma at a community clinic. Thirty-six hours post-step-up dose, he develops fever and confusion. The ED is unfamiliar with bispecifics; the APP is unsure if it's CRS, ICANS, or infection.
Please share one actionable plan you will implement to strengthen safe, efficient, and coordinated delivery of bispecific antibody (bsAb) therapy for patients with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL) across your practice or health system.
Establish clear escalation pathways and shared-care protocols between academic and community sites to standardize toxicity monitoring, supportive care access, and quality metrics that ensure continuity, safety, and equity for patients receiving bsAbs.
Interested in becoming a Group Leader?
Group Leaders are supported by a PhD-level education specialist who will serve as the Gather-ed Group Facilitator. Apply Now
